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Background: Chronic spinal cord injury (SCI) induces immune depression in patients, which contributes to their
higher risk of developing infections. While defects in humoral immunity have been reported, complications in T-cell
immunity during the chronic phase of SCI have not yet been explored.
Methods: To assess the impact of chronic SCI on peripheral T-cell number and function we used a mouse model
of severe spinal cord contusion at thoracic level T9 and performed flow cytometry analysis on the spleen for T-cell
markers along with intracellular cytokine staining. Furthermore we identified alterations in sympathetic activity in
the spleen of chronic SCI mice by measuring splenic levels of tyrosine hydroxylase (TH) and norepinephrine (NE). To
gain insight into the neurogenic mechanism leading to T-cell dysfunction we performed in vitro NE stimulation of
T-cells followed by flow cytometry analysis for T-cell exhaustion marker.
Results: Chronic SCI impaired both CD4+ and CD8+ T-cell cytokine production. The observed T-cell dysfunction
correlated with increased expression of programmed cell death 1 (PD-1) exhaustion marker on these cells. Blocking
PD-1 signaling in vitro restored the CD8+ T-cell functional defect. In addition, we showed that chronic SCI mice had
higher levels of splenic NE, which contributed to the T-cell exhaustion phenotype, as PD-1 expression on both CD4+
and CD8+ T-cells was up-regulated following sustained exposure to NE in vitro.
Conclusions: These studies indicate that alteration of sympathetic activity following chronic SCI induces CD8+
T-cell exhaustion, which in turn impairs T-cell function and contributes to immune depression. Inhibition of the
exhaustion pathway should be considered as a new therapeutic strategy for chronic SCI-induced immune depression.
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Spinal cord injury (SCI) is a devastating condition that
affects more than 200,000 people in the United States.
Besides the obvious locomotor impairments, SCI brings
about a wide array of metabolic and immune problems
for those patients, especially now that their life expect-
ancy has considerably increased [1]. Patients suffering
from SCI are at higher risk than the general population
of developing infections and their prognosis is often
much poorer [2-4]. Originally the immunodeficiency
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However, the extent of immune depression is much
more pronounced with injuries to the central nervous
system than with any other stressful traumatic events
suggesting a neurogenic component to the immunodefi-
ciency [5,6]. Over the past decade it became clear that
the immune system is in close relationship with the ner-
vous system and that neuro-immune communications
are essential to develop an appropriate immune response
to pathogens [7,8].
The immune organs are highly innervated by the sym-
pathetic nervous system (SNS) [9], and through the re-
lease of norepinephrine (NE), the SNS has been reported
to regulate the functions of both innate and adaptive im-
mune cells [10]. Tracing studies using pseudorabies virus. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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segments from level 3 to level 12 [11]. Thus, traumatic
injury to the thoracic spinal cord may disrupt the sym-
pathetic preganglionic neurons at the injury level and
in turn may alter the sympathetic innervation of the
spleen.
Recent studies using rodent SCI models have begun to
investigate the effect of chronic SCI (> four weeks) on
the adaptive immunity. Chronic SCI impairs the anti-
body response in both mice and rats [12-14]. The ger-
minal center B-cells’ number and function are also
impaired by chronic SCI [13]. Importantly, T-cells have a
key role in both antibody mediated and cytotoxic im-
mune response to viral infections such as influenza [15].
It has been shown that CD4+ T-cell effector function to
mouse hepatitis virus (MHV) is suppressed following
SCI in the acute phase [16]. However, whether or not
SCI alters T-cell function over a chronic time period has
yet to be explored.
T-cell exhaustion and its correlation with immune de-
fects have been widely studied in chronic viral infection,
aging and cancer research in the last decade [17-23]. El-
evated expression of exhaustion markers such as pro-
grammed cell death-1 (PD-1) negatively regulates T-cell
effector function. Blockade of exhaustion marker path-
ways has been shown to restore the T-cell functional de-
fects in both chronic virus infection and tumor models
[18,24-28]. Higher viral load, persistent exposure to anti-
gen and loss of CD4+ T-cell correlates with T-cell ex-
haustion [29]. It is unclear whether T-cell exhaustion is
responsible for chronic SCI-induced immune depres-
sion and whether change in SNS activity affects T-cell
exhaustion.
In the present study, we investigated the impact of
chronic SCI on the peripheral T-cell immunity. We pro-
vide evidence that cytokine production by CD4+ and
CD8+ T-cells from chronically injured mice is impaired
and that this impairment was due to increased expres-
sion of PD-1 exhaustion marker on splenic T-cells.
Blocking PD-1 rescued the functional defects of T-cells
isolated from chronic SCI mice. We also demonstrated
that increased levels of splenic NE following SCI may
contribute to increased PD-1 expression on T-cells as
we showed in vitro that PD-1 expression is increased on
T-cells in presence of sustained levels of NE. Collect-
ively, these findings suggest that deregulation of splenic
sympathetic activity by chronic SCI induces T-cell ex-




Age-matched female C57BL/6 mice were purchased
from The Jackson Laboratory or bred in the AnimalFacility of the Miami Project to Cure Paralysis. All mice
used for the experiments were four to seven months old
when sacrificed. All animal protocols were approved by
the University of Miami Institutional Animal Care and
Use Committee (IACUC) and are in accordance with
National Research Council guidelines for the care and
use of laboratory animals.
Spinal cord injury
Severe spinal contusion injury was induced using the In-
finite Horizon Impactor (Precision Systems and Instru-
mentation, LLC). Briefly, three to four month-old mice
(weight ± SD: 19.9 ± 1.5 g) were acclimated for one week
prior to surgery. Mice were anesthetized by intraperi-
toneal injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg). A laminectomy was performed at vertebrae
thoracic level 9 (T9). The underlying spinal cord was ex-
posed and injured by the tip of the contusion device at a
predetermined impact force of 70 kDynes (severe injury).
After surgery, mice were housed separately and received
daily subcutaneous injections of lactated Ringer’s solu-
tion to prevent fluid loss and gentamicin (40 mg/kg) to
prevent urinary tract infections. Manual bladder expres-
sion (twice daily) was performed until mice regain bladder
function. After about three weeks mice were reunited with
their original cage mates.
Splenocyte isolation
Mice were anesthetized and a laparotomy was performed
to expose and excise the spleen. Single cell suspensions
of individual spleens were prepared by mashing the
spleens through a 100-μm nylon mesh strainer. Strainers
were washed with Hank’s Balanced Salt Solution (HBSS,
Gibco). Red blood cells were lysed with ACK lysing buf-
fer (Gibco, Grand Island, NY). For flow cytometry stain-
ing, splenocytes were washed with HBSS, resuspended
in flow cytometry (FACS) staining buffer (HBSS, 1%
BSA, 0.05% sodium azide). For ex vivo stimulation assay,
splenocytes were washed with complete RPMI (RPMI
1640, 5% FBS, 100 U/mL penicillin, 100 μg/mL strepto-
mycin). The number of live cells was determined by trypan
blue exclusion staining.
Flow cytometry
Prior to staining, all samples were incubated with 5 μg/mL
Fc receptor block (anti-mouse CD16/32, Biolegend, San
Diego, CA.) for five minutes on ice to prevent nonspe-
cific staining. Cells were stained for surface markers by
adding the following conjugated Abs: APC-anti-CD11c
(Biolegend, San Diego, CA. clone N418, 1:100), PE-anti-
CD274 (Biolegend, San Diego, CA. PD-L1, clone 10F.9G2,
1:100), APC/Cy7-anti-CD4 (Biolegend, San Diego, CA.
clone GK1.5, 1:200), Alexa Fluor 488-anti-CD8a (Biolegend,
San Diego, CA. clone 53-6.7, 1:200) and PE/Cy7-anti-CD279
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APC-efluor780-anti-B220 (eBioscience, San Diego, CA.
clone HIS24, 1:200), PE-Cy7-anti-CD11b (eBioscience,
San Diego, CA. clone M1/70, 1:200), PE/Cy7-anti-CD45
(eBioscience, San Diego, CA. clone 30-F11, 1:10,000),
FITC-anti-CD45 (eBioscience, San Diego, CA. clone 30-F11,
1:200), Alexa Fluor 488-anti-CD3e (eBioscience, San
Diego, CA. clone 145-2C11, 1:200), efluor450-anti-CD3
(eBioscience, San Diego, CA. clone 17A2, 1:200), APC-
anti-CD4 (eBioscience, San Diego, CA. 1:100), PE-anti-
CD4 (eBioscience, San Diego, CA. clone GK1.5, 1:200),
APC-anti-CD8a (eBioscience, San Diego, CA. clone 53-
6.7, 1:200), PE-anti-CD8a (eBioscience, San Diego, CA.
clone 53-6.7, 1:100). For surface antibody staining, cells
were then fixed overnight with FACS buffer containing 1%
paraformaldehyde and resuspended in FACS buffer. For
detection of dead/live cells, unfixed cells were incubated
with 5 μL of 7-AAD Viability Staining Solution (Biolegend,
San Diego, CA) and immediately analyzed by flow cy-
tometry. For intracellular antibody staining, cells are
fixed, permeablized and stained using Foxp3 staining
Kit (eBiosicence, San Diego, CA.) according to the manu-
facture’s protocol. Intracellular marker expression was
quantified using the following conjugated Abs: eFluor450-
anti-IFN-γ (eBioscience, San Diego, CA. 1:100) and PerCP-
eFluor 710-anti-TNFα (eBioscience, San Diego, CA. 1:100).
All antibody incubations were performed for 20 minutes
at 4°C. The following isotype control antibodies were used
for flow cytometry gating: PerCP-eFluor710 IgG1κ (clone
eBRG1, eBioscience, San Diego, CA), eFluor450 IgG1κ
(clone eBRG1, eBioscience, San Diego, CA), APC/Cy7
IgG2b κ (clone RTK4530, Biolegend, San Diego, CA) and
APC IgG2a κ (clone eBR2a, eBioscience, San Diego, CA).
Cells were analyzed using BD LSRII, BD LSR Fortessa-
HTS or BD FACS. Canto-II flow cytometers and were
quantified using FACS-Diva Version 6.1.3 software
(BD Biosciences, San Jose, CA). Gating strategies were
described in Additional files 1 and 2.
T-cell stimulation
Splenocytes were isolated and counted as above. For
PMA/ionomycin stimulation, 106 splenocytes were cul-
tured in 1 mL of complete RPMI in a 24-well plate with
50 ng/mL phorbol myristate acetate (PMA, Sigma, St.
Louis, MO), 0.75 μg/mL ionomycin calcium salt (Sigma,
St. Louis, MO) and 1 μL GolgiPlug protein transport in-
hibitor (BD Biosciences, San Jose, CA) for four hours at
37°C, 5% CO2. For the PD-1 blockade assay, 10 μg/mL
anti-PD-1 blocking antibody (Biolegend, San Diego, CA)
or 10 μg/mL rat IgG2a, κ isotype control (Biolegend,
San Diego, CA) was added to the complete RPMI along
with PMA and ionomycin. For the T-cell receptor (TCR)
activation assay, 96-well plates were coated with 10 μg/mL
anti-mouse CD3e (eBioscience, San Diego, CA. clone145-2C11) overnight at 4°C. The next day splenocytes
(106/well) were added in 200 μL T-cell medium (RPMI,
10% FBS, 55 μM 2-mercaptoethanol, 2 mM L-glutamine,
10 μg/ml gentamicin and 10 μM HEPES) along with
2 μg/mL of anti-mouse CD28 (eBioscience, San Diego,
CA. clone 37.51) and 50 U/mL of recombinant human
IL-2 (Peprotech, Rocky Hill, NJ) and cultured for three
days at 37°C in 5% CO2. Brefeldin A (eBioscience, San
Diego, CA) was added six hours before intracellular
cytokine cell staining.
ELISA measurement of cytokine concentration
Supernatants from T-cell stimulation (three-days of TCR
activation as described above) were collected and frozen
at −80°C. TNF-α and IFN-γ protein levels were measured
using the Mouse TNF-α ELISA Ready-SET-Go! Kit
(eBioscience, San Diego, CA) and the Mouse IFN- γ
ELISA Ready-SET-Go! Kit (eBioscience, San Diego, CA),
respectively, according to the manufacture’s protocol. For
TNF-α, supernatants were diluted 1:5 and for IFN-γ 1:50.
T-cell proliferation assay
Isolated splenocytes from CT and chronic SCI mice were
resuspended in 1 ml PBS containing 5% FBS. Immediately
after addition of carboxyfluorescein diacetate succinimidyl
ester (CFSE, 5 μM) cells were mixed thoroughly and incu-
bated for five minutes at room temperature. Following
incubation, free CFSE was quenched with 10 ml T-cell
medium (RPMI, 10% FBS, 2-mercaptoethanol (55 μM),
l-glutamine (2 mM), gentamicin (10 μg/ml) and HEPES
(10 μM)). After extensive washes in T-cell medium, cells
were diluted to 1 × 106/ml and seeded in an anti-CD3e-
coated 96-well plate at 200 μl/well. Anti-mouse CD28
(eBioscience, San Diego, CA, clone 37.51, 2 μg/mL) and
10 U/mL of recombinant human IL-2 (Peprotech, Rocky
Hill, NJ) were also added to these wells for further
stimulation. Cells were subsequently allowed to prolifer-
ate at 37°C in 5% CO2 for three days before staining
using APC anti-CD4 and PE anti-CD8. Flow cytometry
data (20,000 events gated on CD4 or CD8) were ac-
quired on LSR II flow cytometer (BD Biosciences, San
Jose, CA). Data analysis was performed using Flowjo
Software (TreeStar Inc, Ashland, OR).
T-cell enrichment
T-cell enrichment was obtained by plating splenocytes in
a 75 cm2 cell culture flask coated with 100 μg/mL goat
anti-mouse IgG + IgM (H + L) (Jackson Immuno Research
Laboratories, West Grove, PA) for one hour, followed by
re-plating the non-adherent cells in another 75 cm2 cell
culture flask for one hour at 37°C, 5% CO2. The non-
adherent T-cells were then collected and washed with
complete RPMI before used in stimulation assays.
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To measure the effects of NE on T-cell exhaustion, T-cells
from uninjured (CT) mice were enriched and counted as
described above. Prior to cell culture, a fresh stock solu-
tion of 100 mM NE was prepared by dissolving 50 mg of
(−)-norepinephrine (Sigma, St. Louis, MO) in 2.96 mL of
0.4 N perchloric acid (PCA) containing 5 mM glutathione.
Enriched T-cells (2 × 105) were cultured in 200 μL of
cRPMI with either NE diluted to a final concentration
of 10 μM or an equivalent volume of perchloric acid/
glutathione solution as vehicle control. Cells were cul-
tured for one day, two days or three days at 37°C, 5%
CO2 and harvested for flow cytometry analysis. Culture
medium with NE or vehicle was changed daily. To
analyze T-cell cytokine production following NE expos-
ure, we replaced the media with cRPMI in a 24-well
plate with 50 ng/mL phorbol myristate acetate (PMA, Sigma,
St. Louis, MO), 0.75 μg/mL ionomycin calcium salt (Sigma,
St. Louis, MO) and brefeldin A solution (eBioscience,
San Diego, CA) for four hours at 37°C, 5% CO2.
Protein extraction and Western blotting
Spleens were harvested and homogenized in radio-
immunoprecipitation assay lysis buffer (10 mM Na-
phosphate pH 7.2, 150 mM NaCl, 1% Igepal CA-630, 1%
Na-deoxycholate, 0.1% sodium dodecyl sulfate, 2 mM eth-
ylenediaminetetraacetic acid) containing complete prote-
ase inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN) and phosphatase inhibitor cocktail 3 (Sigma, St. Louis,
MO). The samples were mixed end-over-end at 4°C for 20
minutes and lysates were centrifuged at 4°C for 15 mi-
nutes at 14,000 rpm. The protein concentrations in the
supernatant were quantified using DC Protein Assay Kit
(Bio-Rad, Hercules, CA). Protein samples (20 μg) and pro-
tein prestained standards (Precision Plus, Sanborn, NY)
were resolved on a 10% sodium dodecyl sulfate polyacryl-
amide gel electrophores (SDS-PAGE) and then transferred
to nitrocellulose membrane (Bio-Rad, Hercules, CA).
Membranes were blocked for one hour at room temperature
in Tris-buffered saline with Tween-20 (TBST) containing
5% non-fat dry milk followed by incubation overnight at 4°C
with rabbit anti-tyrosine hydroxylase antibody (1:1,000,
Calbiochem, San Diego, CA). After extensive washes in
TBST, a conjugated horseradish peroxidase anti-rabbit
secondary antibody was then applied for 30 minutes at
room temperature. Immunoreactive signals were visualized
using enhanced chemiluminescence (ECL) Western blotting
detection reagents (Amersham, Piscataway, NJ). The protein
bands were quantified with Quantity One software
(Bio-Rad, Hercules, CA) and normalized to β-actin.
Measurement of splenic norepinephrine
Spleens were snap frozen in liquid nitrogen and ground to
powder taking care to avoiding any thawing. Glutathione/PCA solution (0.4 N perchloric acid with 5 mM gluta-
thione) was added to the powder at 1 mL per 100 mg of
tissue. Following homogenization, the samples were
centrifuged for 15 minutes at 14,000 rpm and 4°C and
the supernatants were stored at −80°C. Concentrations
of NE in the supernatant were measured by the Hormone
Assay & Analytical Services Core at Vanderbilt University
School of Medicine.
Data analysis
All experimental data are expressed as mean ± standard
error of the mean (SEM). Student’s t-test was applied for
comparison between two groups. Graphpad Prism
(Graphpad Software, La Jolla, CA, USA) was used for
statistical analysis. P < 0.05 was considered as significant.
Results
Chronic SCI alters the function of CD4+ and CD8+ T-cells
but not their numbers
Several studies have shown that following acute SCI
(< seven days post-injury) there was a dramatic reduction
in the number of splenic T-cells [30-32]. To evaluate the
impact of spinal cord injury on spleen function at a
chronic time point, namely five to seven weeks post-SCI,
we first assessed the cell numbers with a focus on T-cells.
As shown in Figure 1A, the spleen weight was not sig-
nificantly different between the uninjured and chronic
SCI groups (uninjured: 77.1 ± 2.1 mg; chronic SCI:
70.6 ± 5.3 mg; P = 0.27) nor was the total spleen cell num-
ber (uninjured: 86.5 ± 8.4 × 106; chronic SCI: 89.4 ± 9.2 × 106;
P = 0.82) (Figure 1B). Furthermore, the spleens of unin-
jured and chronic SCI mice contained similar numbers of
T-cells (uninjured: 27.0 ± 1.9 × 106; chronic SCI: 22.6 ±
2.4 × 106; P = 0.16) (Figure 1C, D) with no significant
differences in the numbers of CD4+ T-cells (uninjured:
12.4 ± 1.0 × 106; chronic SCI: 10.0 ± 0.7 × 106; P = 0.06)
or CD8+ T-cells (uninjured: 11.5 ± 0.8 × 106; chronic
SCI: 9.3 ± 1.2 × 106; P = 0.14) (Figure 1C, E) between
groups.
Effective T-cell response against pathogen requires the
production of cytokines such as IFN-γ and TNF-α [33-36].
To evaluate the function of these T-cells, we isolated sple-
nocytes from the spleens of uninjured and chronic SCI
mice and stimulated them ex vivo with PMA/ionomycin.
As shown in Figure 2A and 2B, a significantly smaller
percentage of CD4+ T-cells produced IFN-γ following
stimulation (uninjured: 8.3 ± 0.5%; chronic SCI: 5.8 ±
0.4%; P = 0.0005) also correlating with a significantly
reduced number of IFN-γ+CD4+ T-cells in chronically
injured mice compared to controls (uninjured: 1.0 ±
0.1 × 106; chronic SCI: 0.7 ± 0.1 × 106; P = 0.02). The per-
centage or number of CD4+ T-cell expressing TNF-α
(Figure 2A, B) following stimulation was not significantly
different between chronic SCI and control (percentage:
Figure 1 (See legend on next page.)
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Figure 2 Impaired T-cell cytokine production in response to PMA/ionomycin stimulation after chronic spinal cord injury (SCI). Isolated
splenocytes (1 × 106) from uninjured (CT) or T9-SCI mice at chronic phase after injury (SCI) were stimulated ex vivo with PMA/ionomycin in the
presence of brefeldin A for four hours and then processed for flow cytometry analysis. The unstimulated controls were incubated only with brefeldin
A. (A) Representative dot plots show the percentage of IFN-γ+ and TNF-α+ cells in gated CD4+ T-cells following PMA/ionomycin stimulation compared
to unstimulated or isotype control. (B) Bar graph represents the mean ± SEM percentages and numbers of cytokine producing CD4+ T-cell in response
to PMA/ionomycin stimulation. (C) Representative dot plots show the percentage of IFN-γ+ and TNF-α+ cells in gated CD8+ T-cells following
PMA/ionomycin stimulation compared to unstimulated or isotype control. (D) Bar graph represents the mean ± SEM percentages and numbers
of cytokine producing CD8+ T-cells in response to PMA/ionomycin stimulation. Ten thousand events gated on live singlets were collected.
n = 14 for CT, n = 12 for SCI. Data were pooled across four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, one-tailed Student’s t-test.
(See figure on previous page.)
Figure 1 The number of splenocytes and splenic T-cells are not changed during chronic spinal cord injury (SCI). (A) Bar graph represents
the mean ± SEM spleen weights of uninjured mice (CT) and T9-SCI mice at chronic phase after injury (SCI). n = 12 mice/group. Data are pooled
across three independent experiments. (B) Bar graph represents the mean ± SEM of total splenocyte numbers for CT and SCI mice. n = 17 for CT,
n = 19 for SCI. Data were pooled across four independent experiments. (C) Representative dot plots show the percentage of T-cells (CD45+CD3+)
in live splenocytes (upper panels), as well as the percentages of CD4+ T-cells (CD4+CD8−, bottom right quadrant) and CD8+ T-cells (CD4−CD8+,
upper left quadrant) in gated T-cells (bottom panels). (D) Bar graph represents the mean ± SEM number of splenic T-cells in CT and SCI mice.
(E) Bar graph show the mean ± SEM numbers of splenic CD4+ T-cells and CD8+ T-cells in CT and SCI mice. Ten thousand events gated on live
singlets were collected. n = 12 mice/group. Data are pooled across three independent experiments. No statistical difference was detected
between the two groups. P > 0.05, two-tailed Student’s t-test.
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number: uninjured: 1.3 ± 0.1 × 106; chronic SCI: 1.4 ±
0.2 × 106; P = 0.38). However, the percentage and number
of CD8+ T-cells expressing TNF-α was significantly re-
duced following chronic SCI (percentage: uninjured: 7.7 ±
0.7%; chronic SCI: 6.0 ± 0.6%; P = 0.04; cell number: un-
injured: 0.80 ± 0.06 × 106; chronic SCI: 0.60 ± 0.05 × 106;
P = 0.007) (Figure 2C, D), when neither the percentage
nor the number of IFN-γ+CD8+ T-cells was changed
by chronic SCI (percentage: uninjured: 20.1 ± 1.1%;
chronic SCI: 18.5 ± 0.9%; P = 0.14; cell number: uninjured:
2.2 ± 0.2 × 106; chronic SCI: 1.9 ± 0.2 × 106; P = 0.17)
(Figure 2C, D).
To confirm the functional impairment of T-cell cytokine
production isolated from chronically injured mice, we re-
peated the experiment using anti-CD3/anti-CD28 stimula-
tion protocol which is more physiologically relevant. As
shown in Figure 3A, B, the percentages of CD4+ T-cells
producing IFN-γ or TNF-α following anti-CD3/anti-CD28
stimulation were significantly decreased in the SCI group
(IFN-γ: uninjured: 2.2 ± 0.2%; chronic SCI: 1.4 ± 0.1%;
P = 0.005; TNF-α: uninjured: 2.2 ± 0.2 × 106; chronic
SCI: 1.4 ± 0.2 × 106; P = 0.008). CD8+ T-cells from chronic
SCI mice also show a reduction in the percentages of IFN-
γ and TNF-α expressing cells in response to anti-CD3/
anti-CD28 stimulation (IFN-γ: uninjured: 6.2 ± 0.7%;
chronic SCI: 2.6 ± 0.4%; P = 0.001; TNF-α: uninjured:
2.8 ± 0.4 × 106; chronic SCI: 1.6 ± 0.3 × 106; P = 0.03)
Figure 3C, D. To further confirm the deficiency in
cytokine production, we performed ELISA on the
supernatant of these stimulated T-cells and found a
significant reduction in the concentration of IFN-γ
(uninjured: 123 ± 4 ng/ml; chronic SCI: 103 ± 5 ng/ml;
P = 0.005) and TNF-α (uninjured: 0.33 ± 0.02 ng/ml;
chronic SCI: 0.25 ± 0.01 ng/ml; P = 0.004) (Figure 3E).
Since stimulation with anti-CD3/anti-CD28 in presence
of IL-2 induces proliferation of T-cells, we also evaluated
the proliferative capabilities of these cells isolated from
chronically injured mice using CFSE (Figure 4A, B). We
did not find any significant difference in the ability of ei-
ther CD4+ T-cells or CD8+ T-cells to proliferate compared
to CT mice.
Collectively, we showed that both CD4+and CD8+ T-cells
isolated from chronic SCI mice have defects in cytokine
production, which may contribute to the chronic SCI
induced immunodeficiency.
Increased expression of exhaustion marker PD-1 on
T-cells isolated from chronic SCI mice
T-cell exhaustion indicated by increased expression of ex-
haustion markers such as PD-1, cytotoxic T-lymphocyte
antigen 4 (CTLA-4), T-cell immunoglobulin mucin-3
(TIM-3) and lymphocyte activation gene-3 (LAG-3) was
shown to correlate with T-cell dysfunction in chronic viralinfection models and aging animals [23,25,29,37-40]. To
examine whether the T-cell impairment in cytokine pro-
duction observed in chronic SCI mice was associated
with T-cell exhaustion, we measured the expression of
exhaustion markers on both CD4+ T-cells and CD8+ T-
cells. The percentage of PD-1 expressing cells in both
CD4+ T-cells and CD8+ T-cells was significantly higher
in the spleen of chronic SCI mice compared with unin-
jured controls (CD4+PD1+ T-cells: uninjured: 12.9 ± 1.3%;
chronic SCI: 18.0 ± 1.7%; P = 0.02. CD8+PD1+ T-cells: un-
injured: 3.4 ± 0.2%; chronic SCI: 5.0 ± 0.4%; P = 0.003)
(Figure 5A). The number of splenic CD8+PD-1+ cells was
also significantly increased in the chronic SCI mice (unin-
jured: 0.43 ± 0.05 × 106; chronic SCI: 0.59 ± 0.04 × 106;
P = 0.01) (Figure 5B). However, the number of splenic
CD4+PD-1+ cells was not significantly changed by chronic
SCI (uninjured: 1.9 ± 0.4 × 106; chronic SCI: 2.7 ± 0.3 × 106;
P = 0.07) (Figure 5B). The expression of other exhaustion
markers including CTLA-4, TIM-3 and LAG-3 on T-cells
was not increased by chronic SCI (data not shown).
Increased expression of PD1 ligand on B-cells and
macrophages isolated from chronic SCI mice
We sought to determine whether the ligand for PD-1 re-
ceptor (PD-L1) was up-regulated following chronic SCI,
as engagement of PD-1 ligand with PD-1 induces T-cell
exhaustion signaling. We measured the expression of PD-
L1 on B-cells, macrophages and dendritic cells. Compared
with CT group, the mean fluorescence intensity (MFI)
values for PD-L1 were significantly increased on splenic
B-cells (uninjured: 1,169 ± 38; chronic SCI: 1,451 ± 54;
P = 0.003) and macrophages (uninjured: 1213 ± 34; chronic
SCI: 2061 ± 270; P = 0.03) from the chronic SCI group
(Figure 6A, B). However, PD-L1 expression on den-
dritic cells was similar between CT and SCI groups
(uninjured: 3,074 ± 241; chronic SCI: 3,468 ± 202; P = 0.13)
(Figure 6A, B).
Blocking PD-1 restores cytokine production by CD8+
T-cells
We next asked whether inhibiting PD-1 signaling will re-
store the functional defects in cytokine production ob-
served in the splenic T-cells isolated from chronic SCI
mice. Splenocytes from uninjured mice and chronic SCI
mice were stimulated with PMA/ionomycin in the pres-
ence of either anti-PD-1 or an isotype control antibody.
Compared with splenocytes from uninjured mice, the
splenocytes from chronic SCI mice showed a significant
reduction in the percentage of IFN-γ-expressing CD4+
T-cells (uninjured: 7.0 ± 0.8%; chronic SCI + Isotype: 5.1 ±
0.6%; P = 0.04) (Figure 7A, B) and TNF-α-expressing
CD8+ T-cells (uninjured: 6.9 ± 0.9%; chronic SCI + Iso-
type: 4.2 ± 0.6%; P = 0.009) (Figure 7C, D) after PMA/
Figure 3 Impaired T-cell cytokine production following T-cell receptor (TCR) activation in chronic spinal cord injury (SCI) mice. Isolated
splenocytes (1 × 106) from uninjured (CT) or T9-SCI mice at chronic phase after injury (SCI) were stimulated ex vivo for three days with anti-CD3 +
anti-CD28 + IL-2 or with IL-2 only. Brefeldin A was added six hours before cell collection. Intracellular cytokine staining and flow cytometry analysis
were performed. (A) Representative dot plots show the percentage of IFN-γ+ cells and TNF-α+ cells in gated CD4+ T-cells following three-day
stimulation with anti-CD3 + anti-CD28 + IL-2 or with IL-2 only. (B) Bar graph represents the mean ± SEM percentages of cytokine producing CD4+
T-cell in response to TCR activation. (C) Representative dot plots show the percentage of IFN-γ+ cells and TNF-α+ cells in gated CD8+ T-cells
following three-day stimulation with anti-CD3 + anti-CD28 + IL-2 or with IL-2 only. (D) Bar graph represents the mean ± SEM percentages of cytokine
producing CD8+ T-cells in response to TCR activation. n = 4 for CT, n = 5 for SCI. Twenty thousand events gated on live singlets were collected for flow
cytometry analysis. n = 5 mice per group. *P < 0.05, **P < 0.01, one-tailed Student’s t-test. (E) The concentration of IFN-γ and TNF-α in the supernatant
of stimulated cells was measured by ELISA.
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antibodies. Blocking PD-1 restored the percentage of
CD8+ T-cells expressing TNF-α (chronic SCI + anti-PD-
1: 8.6 ± 1.6%; P = 0.01) (Figure 7C, D). However, IFN-γ
production by CD4+ T-cells from chronic SCI mice was
not restored (chronic SCI + anti-PD-1: 5.4 ± 1.0%; P = 0.43)
(Figure 7A, B).Chronic SCI increases PD-1 expression by altering sympa-
thetic activity
To understand how chronic SCI induces T-cell exhaus-
tion, we investigated whether the activity of the sympa-
thetic nervous system is altered by SCI. As a surrogate
marker of SNS activity we measured the protein expres-
sion level of tyrosine hydroxylase (TH), the rate-limiting
Figure 4 T-cells in vitro proliferation shows no change in the mice with chronic spinal cord injury (SCI). Isolated splenocytes (2 × 105) from
uninjured (CT) or T9-SCI mice at chronic phase after injury (SCI) were labeled with CFSE and stimulated ex vivo for three days with anti-CD3+CD28+IL-2
or with IL-2 only. (A) Representative histogram plots show the CFSE fluorescence of CD4+ T-cells and CD8+ T-cells following three-day stimulation with
anti-CD3+CD28+IL-2 or with IL-2 only. (B) The line graph shows the percentage of CD4+ T-cells and CD8+ T-cells that have undergone zero to five
divisions. Twenty thousand events gated on CD4+ T-cells or CD8+ T-cells were collected. n = 5 mice per group. No statistical difference was detected
between the two groups. P > 0.05, two-tailed Student’s t-tests were performed for each cell division number.
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extract from both control and SCI mice. Compared to
uninjured control, TH expression levels in the spleen of
injured mice was significantly elevated (Figure 8A) and
consistent with significantly higher NE concentrations in
the spleen of those injured mice (uninjured: 0.26 ± 0.03
ng NE/mg spleen; chronic SCI: 0.38 ± 0.05 ng NE/mg
spleen, P = 0.04) (Figure 8B). These results led us to
hypothesize that higher sustained splenic NE levels in
injured mice may contribute to T-cell exhaustion. To
test this hypothesis, we sought to incubate enriched T-
cells from naive mice with 10 μM NE over several days
and assess whether these cells up-regulated PD-1. Since
prolong exposure to NE could be toxic to the cells, we
first determined cell viability. Naïve enriched T-cells
were incubated either with NE or vehicle for one, two
and three days and cell viability was measured by flowcytometry using 7-AAD. As shown in Figure 9, after
three days in culture with NE, T-cell viability was very
low, as reflected by a low percentage of 7-AAD− live
cells (Vehicle: 83.7 ± 3.1%; NE: 11.1 ± 7.7%; P = 0.0009)
(Figure 9A, B). Therefore, we determined the number of
PD-1 expressing T-cell following one and two days of
NE stimulation. As shown in Figure 9C-F, one day of NE
stimulation significantly increased PD-1+CD8+ T-cell
number compared to vehicle-treated cells (Vehicle: 565 ± 46;
NE: 985 ± 75; P= 0.004), when the cell numbers of both
CD4+PD-1+ T-cells (Vehicle: 5,283 ± 439; NE: 6,747 ± 135;
P= 0.02) and CD8+PD-1+ T-cells (Vehicle: 747 ± 72; NE:
1,031 ± 94; P = 0.04) were upregulated after two days of
continuous NE stimulation.
We next determined whether NE stimulation resulted
in defective cytokine production in the enriched T-cells.
Enriched T-cells were incubated for two days with NE
Figure 5 Increased expression of exhaustion marker PD-1 on T-cells isolated from chronic spinal cord injury (SCI) mice. (A)
Representative dot plots show the percentage of PD-1+ cells in gated CD4+ T-cells and CD8+ T-cells from uninjured (CT) and T9-SCI mice at
chronic phase after injury (SCI). (B) Bar graphs show the mean ± SEM numbers of PD-1 expressing CD4+ T-cells and CD8+ T-cells. Twenty thousand
events gated on live singlets were collected. n = 9 for CT mice, n = 11 for SCI mice. Data have been pooled across two independent experiments.
*P < 0.05, one-tailed Student’s t-test.
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kine profile of these cells was characterized after 4 hours
of stimulation. Compared with vehicle control, NE
stimulation significantly reduced both IFN-γ (Vehicle:
4.9 ± 0.3%; NE: 3.5 ± 0.4%; P = 0.02) and TNF-α produc-
tion (Vehicle: 3.5 ± 0.3%; NE: 1.1 ± 0.1%; P = 0.001) of
CD4+ T-cells (Figure 10A, B), as well TNF-α production
(Vehicle: 6.4 ± 0.4%; NE: 3.7 ± 0.7%; P = 0.01) in CD8+
T-cells (Figure 10C, D), These data strongly suggest
that sustained elevated levels of splenic NE followingchronic SCI could induce T-cell exhaustion and dysfunc-
tion of cytokine production.
Discussion
In the present work, we assessed the impact of chronic
SCI on the peripheral immune system and explored the
mechanisms by which traumatic injury to the spinal cord
induces T-cell dysfunction. Using a severe spinal cord
contusion model at thoracic level T9, we demonstrate
that although there was no change in splenic T-cell
Figure 6 Up regulation of PD-l ligand PD-L1 expression on splenic B-cells and macrophages following chronic spinal cord injury (SCI).
(A) Representative histogram plots show PD-L1 expression on gated B220+ B-cells, CD11b+ macrophages and CD11c+ dendritic cells from
uninjured (CT) and T9-SCI mice at chronic phase after injury (SCI). (B) Bar graphs show the mean ± SEM of PD-L1 mean fluorescence intensities
(MFI) in gated B-cells, macrophages and dendritic cells from CT and SCI mice. Ten thousand events gated on live singlets were collected. n = 4
mice per group. *P < 0.05, **P < 0.01, one-tailed Student’s t-test.
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was significantly altered as assessed by ex vivo stimula-
tion with PMA/ionomycin or with anti-CD3/anti-CD28
stimulation. IFN-γ production by CD4+ T-cells and TNF-
α production by CD8+ T-cells in response to PMA/iono-
mycin stimulation were significantly reduced in the cells
isolated from chronically spinal cord injured mice.
Chronic SCI impaired the IFN-γ and TNF-α production
of both CD4+ and CD8+ T-cells following anti-CD3/
anti-CD28 stimulation. We provide evidence that T-cell
exhaustion contributes to SCI-induced T-cell dysfunc-
tion. T-cell expression levels of exhaustion marker PD-1
was significantly increased by chronic SCI, while in vitro
blockade of PD-1 restored CD8+ T-cell function. To our
knowledge, this is the first report showing that chronic
SCI alters T-cell function and increases T-cell exhaus-
tion. Furthermore, the activity of SNS in the spleen is
higher in injured mice. Long-term in vitro exposure to
NE increased PD-1 expressing T-cells and impaired T-cellfunction of cytokine production. This finding suggests that
alterations in the SNS output is involved in the mechan-
ism by which chronic SCI induces T-cell exhaustion, and
highlights the importance of the SNS in the regulation of
T-cell function.
Previous studies in SCI animal models have character-
ized changes in the peripheral immune system occurring
in the acute phase. T-cell loss in the spleen was reported
at one to three days after injury [31,32]. Increased level
of glucocorticoids and NE at acute phase after SCI induces
lymphocyte apoptosis and results in T-cell decrease [41].
However, no significant reduction in the T-cell number
was observed at later time points such as day 7, day 14
and day 28 post-injury [16,31]. Consistent with those stud-
ies, we did not find any significant difference in the num-
ber of either CD4+ or CD8+ T-cell between uninjured and
chronic SCI mice (> five weeks post-injury). These results
indicate that the temporary T-cell loss in the acute phase
after SCI does not persist in the chronic phase. Therefore
Figure 7 Blocking PD-1 restores the TNF-α production by CD8+ T-cells from chronic spinal cord injury (SCI) mice. Splenocytes (1 × 106)
isolated from uninjured mice were stimulated ex vivo with PMA/ionomycin in the presence of brefeldin A for four hours (group: CT). Splenocytes
(1 × 106) isolated from chronic SCI mice were also stimulated ex vivo with the same condition as the CT group, except that 10 μg/mL anti-PD-1
blocking antibody (group: SCI + αPD-1) or 10 μg/mL rat IgG2a, κ isotype (group: SCI + Isotype) were added to the culture. (A) Representative dot
plots show the percentage of IFN-γ+ cells in gated CD4+ T-cells. (B) Bar graph represents the mean ± SEM percentage of IFN-γ+ cells in CD4+
T-cells. (C) Representative dot plots show the percentage of TNF-α+ cells in gated CD8+ T-cells. (D) Bar graph represents the mean ± SEM percentage
of TNF-α+ cells in CD8+ T-cells. Ten thousand events gated on live singlets were collected. n = 9 for CT, n = 11 for SCI + Isotype, n = 11 for SCI + αPD-1.
Data are pooled across three independent experiments. *P < 0.05, **P < 0.01, n.s. no significant difference was detected, P > 0.05,
one-tailed Student’s t-test.
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is more likely due to functional defects of immune cells
rather than their number.
T-cells regulate host immunity against pathogen infec-
tion by secreting cytokines upon activation [36]. We first
used ex vivo PMA/ionomycin stimulation to investigate
the effect of chronic SCI on T-cell cytokine production.
In this study, chronic SCI mice showed a reduction in
IFN-γ production by CD4+ T-cells as well as TNF-α pro-
duction by CD8+ T-cells. We also measured the T-cell
production upon stimulation with anti-CD3/anti-CD28,
which is more relevant to physiological T-cell receptor
activation in vivo. We demonstrated that the cytokine
production by both CD4+ T-cells and CD8+ T-cells are
impaired. These defects could be associated with SCI-
induced immune depression. IFN-γ is a crucial modulator
in multiple immune responses, including macrophage ac-
tivation, major histocompatibility complex (MHC) I and
MHC II antigen presentation up-regulation, lymphocyte
recruitment, CD4+ T-helper response and inhibition of
viral replication. The deregulation of IFN-γ production
may contribute to the impaired capacity to combat infec-
tion in chronic SCI patients [33]. TNF-α plays a key rolein both host inflammatory and cytotoxic responses against
pathogens [42]. Specifically, during viral infection, TNF-α
produced by cytotoxic T-cells is responsible for apoptosis
and lysis of virus-infected cells [34,35]. Therefore, insuffi-
cient TNF-α production by T-cells is a potential cause of
SCI-induced immunodeficiency. Interestingly, some stud-
ies have suggested a role for TNF-α in forming the germi-
nal center and generating humoral responses [43-45].
Alteration in TNF-α production by T-cell in injured mice
may contribute to their defects in mounting an appropri-
ate antibody response.
T-cell exhaustion has been well studied in the last decade
for its role in T-cell dysfunction and immunodeficiency. It
was first described in a lymphocytic choriomeningitis virus
(LCMV) chronic infection mouse model as a virus-specific
CD8+ T-cell population which cannot elaborate efficient
antiviral effectors’ function [17]. Since then, T-cell exhaus-
tion has been investigated in many chronic viral infections
including human immunodeficiency virus (HIV), hepatitis
B virus and hepatitis C virus, and cancer as well as aging
models [18-23,25,46]. To our knowledge, our study is the
first to show T-cell exhaustion in a SCI model. Previous
studies have demonstrated a correlation between higher
Figure 8 Chronic spinal cord injury (SCI) increases the
sympathetic activity in the spleen. (A) Western blot quantification
of tyrosine hydroxylase (TH) in the spleens of uninjured mice (CT) and
chronic SCI mice (SCI). Data are normalized to the expression of β-actin.
Bar graph represents the mean ± SEM of TH expression in the spleen
protein extract and are expressed as percentage of CT. n = 4 mice/group.
Data represents two independent experiments. *P < 0.05, two-tailed
Student’s t-test. (B) Bar graph represents the mean ± SEM of NE
concentration (ng/mg) in the spleen homogenates from CT and SCI
mice. n = 5 mice/group. *P < 0.05, one-tailed Student’s t-test.
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T-cells [18,24,26]. Herein, we showed that chronic SCI
mice have a significantly higher number of CD8+ T-cells
expressing PD-1 along with increased expression of PD-
L1, the ligand for PD-1, on B-cells and macrophages.
Moreover, the production of TNF-α by CD8+ T-cells was
restored in vitro by blocking PD-1 signaling. These results
suggest that higher PD-1 expression contributes to SCI-
induced CD8+ T-cell dysfunction. However, the number
of CD4+ T-cells expressing PD-1 was not significantly up-
regulated by chronic SCI and blocking PD-1 failed to re-
store IFN-γ production by CD4+ T-cells suggesting that
other mechanisms are involved in SCI-induced CD4+
T-cell dysfunction.
We next explored how chronic SCI increases PD-1 ex-
pression on CD8+ T-cells. Since the spleen is innervated
and modulated by the SNS, disruption of the sympa-
thetic preganglionic neurons at the injury level may lead
to altered SNS output to the spleen. Post-acute phase
SCI causes reorganization of synapses on the sympa-
thetic preganglionic neurons and reinnervation of the
sympathetic terminals at the target organs [47-49]. Our
results showed higher levels of TH in the splenic protein
extract from injured animals compared to uninjured
controls. As the rate-limiting enzyme for catecholamine
synthesis, TH has been used to identify catecholamine
containing noradrenergic terminals in the spleen [50,51].
Elevated TH levels in the spleen of chronic SCI mice
correlated with higher splenic NE levels. These data
could be explained by increased sympathetic innerv-
ation, higher catecholamine levels per cell or more en-
dogenous catecholamine produced by lymphocytes in
the spleen [52,53]. NE has been reported to regulate the
functions of immune cells [10]. Particularly, experimen-
tal induction of autonomic dysreflexia in chronic SCI
mice causes splenic NE accumulation, which is involved
in the impaired immune function [14]. We hypothesized
that higher NE levels in the spleen following chronic
SCI were responsible for the increased T-cell exhaustion.
Consistent with this hypothesis, we found that the num-
ber of PD-1 expressing T-cells was increased after pro-
longed exposure to NE in vitro. While it is unclear how
NE regulates PD-1 expression, several transcription fac-
tor pathways have been demonstrated to play a role in
Figure 9 (See legend on next page.)
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Figure 10 Exposure to norepinephrine (NE) in vitro impairs T-cell cytokine production in response to PMA/ionomycin stimulation.
Enriched splenic T-cells (106 cells/ml) were cultured with 10 μM NE or its vehicle (Vehicle) in vitro. After two days of NE exposure, cells were stimulated
with PMA/ionomycin for four hours in the presence of brefeldin A. Intracellular cytokine staining and flow cytometry analysis were performed
to measure cytokine production. (A) Representative dot plots show the percentage of IFN-γ+ cells and TNF-α+ cells in gated CD4+ T-cells following
PMA/ionomycin stimulation or with brefeldin A only (unstimulated). (B) Bar graph represents the mean ± SEM percentages cytokine producing
CD4+ T-cell in response to PMA/ionomycin stimulation. (C) Representative dot plots show the percentage of IFN-γ+ cells and TNF-α+ cells in gated
CD8+ T-cells following PMA/ionomycin stimulation or with brefeldin A only (unstimulated). (D) Bar graph represents the mean ± SEM percentages of
cytokine producing CD8+ T-cells in response to PMA/ionomycin stimulation. Ten thousand events gated on lymphocytes were collected. Experiments
were performed in triplicate, *P < 0.05, **P < 0.01, one-tailed Student’s t-test.
(See figure on previous page.)
Figure 9 Norepinephrine (NE) up-regulates PD-1 expression on T-cells in vitro. Enriched splenic T-cells (106 cells/ml) were stimulated with
10 μM (NE) or its vehicle (Vehicle) in vitro for one to three days. Cells were collected and processed for flow cytometry. (A) Representative
histograms show the 7-AAD fluorescence and the percentage of live cells (7-AAD−) in gated singlet lymphocytes. (B) Bar graph shows the mean ± SEM
percentage of live cells (7-AAD−) following one to three days of in vitro culture with NE or vehicle. Experiments were performed in triplicate. *P < 0.05,
***P < 0.001, two-tailed Student’s t-test. (C) Representative dot plots show the percentage of PD-1+ cells in gated live CD4+ T-cells. (D) Bar graph
represents the mean ± SEM number of CD4+ PD-1+ live cells per well after one and two days of NE or vehicle treatment. (E) Representative dot plots
show the percentage of PD-1+ cells in gated live CD8+ T-cells. (F) Bar graph represents the mean ± SEM number of live CD8+PD-1+ cells per well after
one and two days of NE or vehicle treatment. Ten thousand events gated on singlet lymphocytes were collected. Experiments were performed in
triplicate. *P < 0.05, **P < 0.01, one-tailed Student’s t-test.
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induced maturation protein 1 (Blimp-1), nuclear factor
of activated T-cells cytoplasmic 1 (NFATc1) and Notch
signaling are regulators of PD-1 gene expression, whereas
high expression of T-bet suppresses PD-1 expression
[54-57]. There is no direct evidence that NE regulates
these transcription pathways in murine splenic T-cells.
However, NE was reported to increase NFATc1 activity
in primary neonatal cardiomyocyte culture [58], suggest-
ing that NE stimulation may up-regulate PD-1 expression
by activating NFATc1. Interestingly, NE stimulation of T-
lineage cells increases the phosphorylation of phosphor 38
mitogen-activated protein kinase (p38 MAPK), which is
involved in the mechanisms by which HIV-1 Nef protein
induces PD-1 expression [59,60]. The activation of the
p38 MAPK pathway may also contribute to the higher
PD-1 expression in our model. Prolonged NE exposure re-
sulted in decreased T-cell cytokine production. Consistent
with our findings, several research groups have found that
activation of β2 adrenergic receptor inhibits IFN-γ pro-
duction in T-cells [61,62]. As NE can affect T-cell function
by multiple mechanisms, such as increased intracellular
cAMP levels [63], we suggest that higher expression of ex-
haustion marker PD-1 on CD8+ T-cells participates in the
mechanisms of NE-induced T-cell dysfunction.
Conclusions
In conclusion, we demonstrated that chronic SCI impaired
both CD4+ and CD8+ T-cell functions. Furthermore, we
identified T-cell exhaustion as a possible mechanism by
which chronic SCI leads to impaired CD8+ T-cell func-
tion. Alterations in the SNS contributed to the exhausted
phenotype of CD8+ T-cells from injured mice. These find-
ings highlight the role of the nervous system and neuro-
transmitters in regulating peripheral immunity. Our study
also sheds light on the development of therapeutic strat-
egies to reduce re-hospitalization and death rate from in-
fection in chronic SCI patients. For example, clinical trials
using antagonist antibodies to PD-1 are now ongoing for
cancer treatment [64]. Our research provides evidence for
the clinical application of PD-1 antibodies in SCI-induced
immune depression treatment. In addition, adrenergic re-
ceptor antagonists, which have been widely used in car-
diovascular diseases, constitute also a potential treatment
to restore immunity in chronic SCI patients.Additional files
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